Addictive Disorders and Pain

Chapter

Abstract

People consume opioids for many reasons, some medically beneficial and others harmful to themselves and to society. It is difficult to conclude that opioid use is harmful by evaluating consumption alone. Consider a population of individuals none of whom have been exposed to opioid use. Within that population are those who do not have addictive disease involving opioids; these individuals will not demonstrate signs and symptoms of addiction whether exposed to opioids or not. A smaller group within the population has addictive disease. Some in this group do not know they have addictive disease simply because they have never been exposed to opioids. Phenotypically, then, they do not have addiction despite the underlying physiology. Another group of individuals, however, will show signs of addiction, resulting from medical or nonmedical use of opioids.

Keywords

Depression Dopamine Morphine Stratification Palladium 

Notes

Acknowledgment

Technical writing and manuscript review are provided by Beth Dove of Medical Communications, Salt Lake City, Utah.

References

  1. 1.
    Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–82.PubMedGoogle Scholar
  2. 2.
    Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Becker WC, Fiellin DA, Gallagher RM, Barth KS, Ross JT, Oslin DW. The association between chronic pain and prescription drug abuse in veterans. Pain Med. 2009;10(3):531–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Hennecke L. Stimulus augmenting and field dependence in children of alcoholic fathers. J Stud Alcohol Drugs. 1984;45(6):486–92.Google Scholar
  7. 7.
    Public policy statement on the rights and responsibilities of healthcare professionals in the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Adopted 2004. Available at http://www.ampainsoc.org/advocacy/pdf/rights.pdf. Accessed 7 Jan 2010.
  8. 8.
    Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. 2004. Available at: http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf. Accessed 7 Jan 2010.
  10. 10.
    Webster LR, Dove B. Avoiding opioid abuse while managing pain: a guide for practitioners. 1st ed. North Branch: Sunrise River Press; 2007. p. 145.Google Scholar
  11. 11.
    National Institutes of Health, U.S. Department of Health and Human Services. Drugs, brains, and behavior: the science of addiction. NIH Pub No. 07–5605. Printed Apr 2007.Google Scholar
  12. 12.
    National Institutes of Health, U.S. Department of Health and Human Services. Research report series. Comorbidity: addiction and other mental illnesses. NIH Pub No. 08–5771. Printed Dec 2008.Google Scholar
  13. 13.
    Zhang Y, Picetti R, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. Neuropsychopharmacology. 2009;34(4):912–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107–12.PubMedCrossRefGoogle Scholar
  15. 15.
    Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain. 2002;18(4 Suppl):S28–38.PubMedCrossRefGoogle Scholar
  16. 16.
    Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage. 1996;11(3):163–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Friedman R, Li V, Mehrotra D. Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med. 2003;4(2):182–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–230.PubMedCrossRefGoogle Scholar
  19. 19.
    Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004;112(1–2):65–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: ­predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Coambs RB, Jarry JL. The SISAP; a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain in general medical practice. Pain Res Manag. 1996;1(3):155–62.Google Scholar
  22. 22.
    Adams LL, Gatchel RJ, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27:440–59.PubMedCrossRefGoogle Scholar
  23. 23.
    Moore TM, Jones T, Browder JH, Daffron S, Passik SD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10(8):1426–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004;26(4):552–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–56.PubMedCrossRefGoogle Scholar
  26. 26.
    Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23(4):307–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. J Addict Dis. 2009;28(2):145–57.PubMedCrossRefGoogle Scholar
  28. 28.
    Donovan DM, Floyd AS. Facilitating involvement in twelve-step programs. Recent Dev Alcohol. 2008;18:303–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Katz N. Patient level opioid risk management: a supplement to the PainEDU.org manual. Newton: Inflexxion, Inc; 2007.Google Scholar
  30. 30.
    Webster LR. Pharmacogenetics in pain management: the clinical need. Clin Lab Med. 2008;28(4):569–79.PubMedCrossRefGoogle Scholar
  31. 31.
    Induru RR, Davis MP. Buprenorphine for neuropathic pain: ­targeting hyperalgesia. Am J Hosp Palliat Care. 2009;26(6):470–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Vadivelu N, Hines RL. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Manag. 2007;3(1):49–58.PubMedGoogle Scholar
  33. 33.
    Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–84.PubMedCrossRefGoogle Scholar

Copyright information

© American Academy of Pain Medicine 2013

Authors and Affiliations

  1. 1.Clinical ResearchSalt Lake CityUSA
  2. 2.Mount Sinai School of MedicineWoonsocketUSA
  3. 3.Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations